- $11.87m
- -$11.39m
- $1.98m
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy
Lipocine Q2 net loss widens as revenue declines
Lipocine Inc reports results for the quarter ended June 30 - Earnings Summary
Lipocine Inc expected to post a loss of 43 cents a share - Earnings Preview
Lipocine Q1 net loss widens on higher R&D costs
Brief: Lipocine Q1 EPS USD -0.54
Brief: Lipocine Inc Spyros Papapetropoulos Resigns As Board Member Effective April 16, 2026
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Lipocine plunges after postpartum depression drug fails main goal in late-stage study
Lipocine's postpartum depression pill misses main goal in late-stage study (updated)
NASDAQ RESUMED AT 08:45 AM
Lipocine's postpartum depression pill misses main goal in late-stage study
Brief: Lipocine Reports Topline Safety & Efficacy Results For LPCN 1154 In Patients With Postpartum Depression
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Brief: Lipocine Files For Common Stock Offering Of Up To $50 Million - SEC Filing
Brief: Lipocine Announces Completion Of Enrollment And Dosing In Phase 3 Trial Of LPCN 1154 In Postpartum Depression